Amarin Corp Plc (AMRN)

[rfj1862]

From the paper re mineral oil

Second,
if mineral oil in the placebo affected statin absorption
in some patients, this might have contributed
to differences in outcomes between the
groups. However, the relatively small differences
in LDL cholesterol levels between the groups
would not be likely to explain the 25% lower risk
observed with icosapent ethyl, and a post hoc
analysis suggested a similar lower risk regardless
of whether there was an increase in LDL
cholesterol level among the patients in the placebo
group. Although JELIS was designed as an
open-label study that did not use a mineral oil
placebo, it showed a 19% lower risk of ischemic
events with statin therapy plus EPA than with
statin therapy alone.